Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug-induced liver injury case–control study in Italy

British Journal of Clinical Pharmacology

Volumn , Issue , 2016, Pages 238-248

  Donati, Monia ^a   Conforti, Anita ^b   Lenti, Maria Carmela ^c   Capuano, Annalisa ^d   Bortolami, Oscar ^e   Motola, Domenico ^a   Moretti, Ugo ^b   Vannacci, Alfredo ^c   Rafaniello, Concetta ^d   Vaccheri, Alberto ^a   Arzenton, Elena ^b   Bonaiuti, Roberto ^c   Sportiello, Liberata ^d   Leone, Roberto ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

^e UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

case control study; DILI; liver injury; nimesulide; NSAIDs

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; CELECOXIB; DEXIBUPROFEN; DICLOFENAC; ETORICOXIB; IBUPROFEN; INDOMETACIN; KETOPROFEN; METOLAZONE; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PIROXICAM; RIFAXIMIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EXPOSURE; FEMALE; HEPATITIS; HUMAN; ITALY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBESITY; PHARMACOEPIDEMIOLOGY; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; TOXIC HEPATITIS;

EID: 84976585220     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12938     Document Type: Article

References (47)

1. Ostapowicz G, Fontana RJ, Schiødt FV, Larson A, Davern TJ, Han SH, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137: 947–54.
2. Reuben A, Koch DG, Lee WM, Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a US multicenter, prospective study. Hepatology 2010; 52: 2065–76.
3. Wei G, Bergquist A, Broomé U, Lindgren S, Wallerstedt S, Almer S, et al. Acute liver failure in Sweden: etiology and outcome. J Intern Med 2007; 262: 393–401.
4. Bechmann LP, Manka P, Best J, Saner FH, Paul A, Canbay A, et al. Drug-induced liver injury as predominant cause of acute liver failure in a monocenter study. Dtsch Med Wochenschr 2014; 139: 878–82.
5. Watkins PB, Seeff LB. Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology 2006; 43: 618–31.
6. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006; 354: 731–9.
7. Abboud G, Kaplowitz N. Drug-induced liver injury. Drug Saf 2007; 30: 277–94.
8. Leise MD, Poterucha JJ, Talwalkar JA. Drug-induced liver injury. Mayo Clin Proc 2014; 89: 95–106.
9. Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcome in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013; 144: 1419–25.
10. Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, et al. Incidence of drug-Induced hepatic injuries: a French population-based study. Hepatology 2002; 36: 451–5.
11. De Valle MB, Av Klinteberg V, Alem N, Olsson R, Björnsson E. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther 2006; 24: 1187–95.
12. de Abajo FJ, Montero D, Madurga M, García Rodríguez LA. Acute and clinically relevant drug-induced liver injury: a population based case–control study. Br J Clin Pharmacol 2004; 58: 71–80.
13. Björnsson ES. Drug-induced liver injury: an overview over the most critical compounds. Arch Toxicol 2015; 89: 327–34.
14. Wehling M. Non-steroidal anti-inflammatory drug use in chronic pain conditions with special emphasis on the elderly and patients with relevant comorbidities: management and mitigation of risks and adverse effects. Eur J Clin Pharmacol 2014; 70: 1159–72.
15. Day RO, Graham GG. Non-steroidal anti-inflammatory drugs (NSAIDs). BMJ 2013; 346: f3195.
16. Ungprasert P, Cheungpasitporn W, Crowson CS, Matteson EL. Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: a systematic review and meta-analysis of observational studies. Eur J Intern Med 2015; 26: 285–91.
17. Motola D, Vargiu A, Leone R, Cocci A, Salvo F, Ros B, et al. Hepatic adverse drug reactions: a case/non-case study in Italy. Eur J Clin Pharmacol 2007; 63: 73–9.
18. Lacroix I, Lapeyre-Mestre M, Bagheri H, Pathak A, Montastruc JL, Club de Reflexion des cabinets de Groupe de Gastro-Enterologie (CREGG), General Practitioner Networks. Nonsteroidal anti-inflammatory drug-induced liver injury: a case–control study in primary care. Fundam Clin Pharmacol 2004; 18: 201–6.
19. Pillans PI, Ghiculescu RA, Lampe G, Wilson R, Wong R, Macdonald GA. Severe acute liver injury associated with lumiracoxib. J Gastroenterol Hepatol 2012; 27: 1102–5.
20. Page M, Christin F, Hayi-Slayman D, Baillon JJ, Ber CE, Delafosse B, et al. Acute liver failure due to a treatment by nimesulide: another case and review. Ann Fr Anesth Reanim 2008; 27: 742–6.
21. Merlani G, Fox M, Oehen HP, Cathomas G, Renner EL, Fattinger K, et al. Fatal hepatoxicity secondary to nimesulide. Eur J Clin Pharmacol 2001; 57: 321–6.
22. FIMEA, Finnish Medicines Agency. The sale of Nimed, an anti-inflammatory analgesic, is temporarily suspended due to its adverse liver effects, 15 March 2002. Available at http://www.fimea.fi/whatsnew/1/0/thesaleofnimedananti-inflammatoryanalgesic,istemporarilysuspendedduetoitsadverselivereffects (last accessed 16 April 2015).
23. AEMPS, Agencia Española de Medicamentos y Productos Sanitarios. Comunicación sobre riesgos de Medicamentos. Ref: 2002/03. Nota Informativa Nimesulida (Guaxan®, Antifloxil®): suspensión cautelar de comercialización, 6 May 2002. Available at http://www.aemps.gob.es/informa/notasInformativaUsoHumano/seguridad/2002/NI_2002-03_nimesulida.htm (last accessed 16 April 2015).
24. EMEA, European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products (CPMP) opinion following an article 31 referral. Nimesulide containing medicinal products, 7 May 2004. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Nimesulide_31/WC500013818.pdf (last accessed 16 April 2015).
25. HPRA, Health Products Regulatory Authority. Nimesulide suspension, 15 May 2007. Available at https://www.hpra.ie/homepage/medicines/safety-notices/item?t=/nimesulide-suspension&id=7d69f825-9782-6eee-9b55-ff00008c97d0 (last accessed 16 April 2015).
26. ANMAT, Administración Nacional de Medicamentos, Alimentos y Tecnología Médica. ANMAT suspende la comercializacion de la droga nimesulide. Boletin para profesionales 2009; XVII (3): 17–24.
27. EMEA, European Agency for the Evaluation of Medicinal Products. Assessment report for Nimesulide containing medicinal products for systemic use, 20 January 2012. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Nimesulide_31/WC500125574.pdf (last accessed 16 April 2015).
28. Traversa G, Bianchi C, Da Cas R, Abraha I, Menniti-Ippolito F, Venegoni M. Cohort study of hepatotoxicity associated with nimesulide and other nonsteroidal anti-inflammatory drugs. BMJ 2003; 327: 18–22.
29. Licata A, Calvaruso V, Cappello M, Craxì A, Almasio PL. Clinical course and outcomes of drug-induced liver injury: nimesulide as the first implicated medication. Dig Liver Dis 2010; 42: 143–8.
30. Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990; 1: 272–6.
31. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment, 2015. Oslo, 2014. Available at http://www.whocc.no/atc_ddd_index/ (last accessed 21 July 2015).
32. Bessone F. Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage? World J Gastroenterol 2010; 16: 5651–61.
33. Unzueta A, Vargas HE. Nonsteroidal anti-inflammatory drug-induced hepatoxicity. Clin Liver Dis 2013; 17: 643–56.
34. Laine L, Goldkind L, Curtis SP, Connors LG, Yanqiong Z, Cannon CP. How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial. Am J Gastroenterol 2009; 104: 356–62.
35. Rostom A, Goldkind L, Laine L. Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients. Clin Gastroenterol Hepatol 2005; 3: 489–98.
36. Björnsson E, Olsson R. Suspected drug-induced liver fatalities reported to the WHO database. Dig Liver Dis 2006; 38: 33–8.
37. Rubenstein JH, Laine L. Systematic review: the hepatotoxicity of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2004; 20: 373–80.
38. Lee CH, Wang JD, Chen PC. Increased risk of hospitalization for acute hepatitis in patients with previous exposure to NSAIDs. Pharmacoepidemiol Drug Saf 2010; 19: 708–14.
39. The Medicines Utilisation Monitoring Centre. National Report on Medicines use in Italy, 2013 (English edition). Available at http://www.agenziafarmaco.gov.it/sites/default/files/OsMed_Report13_Eng.pdf (last accessed 15 July 2015).
40. Borel I, Hedelius F, Baumgartner C, Vial T, Scoazec JY, Dumortier J. Severe acute hepatitis associated with ibuprofen treatment. Gastroenterol Clin Biol 2001; 25: 430–2.
41. Leoz MK, Concejo FB, Fernández JM, Urmeneta JM, Peñuela AM. Ibuprofen-induced cholestatic hepatitis. Gastroenterol Hepatol 2011; 34: 660–1.
42. Douros A, Bronder E, Andersohn F, Klimpel A, Thomae M, Sarganas G, et al. Drug-induced liver injury: results from the hospital-based Berlin Case–Control Surveillance Study. Br J Clin Pharmacol 2015; 79: 988–99.
43. Riley TR, Smith JP. Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis C: a case series. Am J Gastroenterol 1998; 93: 1563–5.
44. Bunchorntavakul C, Reddy KR. Acetaminophen-related hepatotoxicity. Clin Liver Dis 2013; 17: 587–607.
45. Sabaté M, Ibáñez L, Pérez E, Vidal X, Buti M, Xiol X, et al. Paracetamol in therapeutic dosages and acute liver injury: causality assessment in a prospective case series. BMC Gastroenterol 2011; 11: 80.
46. Sabaté M, Ibáñez L, Pérez E, Vidal X, Buti M, Xiol X, et al. Risk of acute liver injury associated with the use of drugs: a multicentre population survey. Aliment Pharmacol Ther 2007; 25: 1401–9.
47. Koffeman AR, Valkhoff VE, Celik S, W't Jong G, Sturkenboom MC, Bindels PJ, et al. High-risk use of over-the-counter non-steroidal anti-inflammatory drugs: a population-based cross-sectional study. Br J Gen Pract 2014; 64: e191–8.